2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow CHEK2 Gene Mutation: new trials by email Literature Review of CHEK2 Gene Mutation trials Research Report on CHEK2 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion Tamoxifen 10 mg Tablet, Intermittent caloric restriction, Step counter Device - BRCA Mutation, PALB2 Gene Mutation | Phase 2 | Completed | European Institute of Oncology | 110 | 2024-06-21 | 2026-09-11 |
| Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - ATM Gene Mutation, ATR Gene Mutation | Phase 2 | Completed | SWOG Cancer Research Network | 51 | 2017-03-03 | 2021-06-23 |
Breast Carcinoma In Situ (1) · Carcinoma, Intraductal, Noninfiltrating (1)
Adenocarcinoma (1) · Breast Diseases (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma in Situ (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Ductal, Lobular, and Medullary (1) · Neoplasms, Glandular and Epithelial (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Tablets (1) · Tamoxifen (1) · talazoparib (1)
European Institute of Oncology (1) · SWOG Cancer Research Network (1)
Canada (1) · Italy (1) · United States (1)
Bernardo Bonanni, MD (1) · Vassiliki Papadimitrakopoulou (1)
2023 (1), U10CA180888 (1)